InMode News

Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating

MT NewswiresApr 12 10:24 ET

InMode Analyst Ratings

BenzingaApr 12 09:58 ET

InMode Analyst Ratings

BenzingaApr 9 11:51 ET

InMode Analyst Ratings

BenzingaFeb 14 14:54 ET

Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)

TipRanksJan 23 04:09 ET

InMode Analyst Ratings

BenzingaJan 18 09:07 ET

Barclays Maintains Overweight on InMode, Lowers Price Target to $33

BenzingaJan 4 08:06 ET

InMode Analyst Ratings

BenzingaJan 4 08:04 ET

Analysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)

TipRanksDec 11, 2023 02:20 ET

Canaccord Genuity Reiterates Hold on InMode, Maintains $22 Price Target

BenzingaDec 7, 2023 10:48 ET

InMode Analyst Ratings

BenzingaDec 7, 2023 10:46 ET

InMode's Long-Term Potential Overcomes Short-Term Headwinds: A Buy Rating Analysis

TipRanksNov 6, 2023 01:23 ET

UBS Cuts InMode to Neutral, Says Macro Factors Clouding Visibility

Seeking AlphaNov 3, 2023 11:56 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), Trupanion (TRUP) and Regeneron (REGN)

TipRanksNov 3, 2023 07:40 ET

UBS Downgrades InMode to Neutral, Lowers Price Target to $24

BenzingaNov 3, 2023 06:41 ET

InMode Analyst Ratings

BenzingaNov 3, 2023 06:40 ET

InMode Faces Revenue Headwinds Amid Challenging Economics: Analyst Cuts Price Target And Estimates

BenzingaOct 13, 2023 14:11 ET

Canaccord Genuity Downgrades InMode to Hold, Lowers Price Target to $22

BenzingaOct 13, 2023 06:24 ET

InMode Analyst Ratings

BenzingaOct 13, 2023 06:23 ET

The Latest Analyst Ratings for InMode

BenzingaAug 1, 2023 08:00 ET